Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update

Clinical Pharmacokinetics
D J Morgan, A J McLean

Abstract

The effects of liver disease on pharmacokinetics and pharmacodynamics are highly variable, and difficult to predict as the mechanisms of these effects are not well understood. Since the majority of the published literature is concerned with cirrhotic liver disease, this review also focuses mainly on this area. Four different theories have been proposed to account for the effects of chronic liver disease with cirrhosis on hepatic drug elimination: the sick cell theory; the intact hepatocyte theory; the impaired drug uptake theory; and the oxygen limitation theory. While some data in support of each of the first 2 theories have been published recently, a large amount of clinical data would appear to refute both of these theories. These clinical data are substantially consistent with the latter 2 theories, which regard the decreased permeability of the capillarised sinusoid as the critical feature in cirrhosis. Further work is required to determine the applicability of each of these theories. In cirrhosis, drug glucuronidation is spared relative to oxidative drug metabolism; however, in advanced cirrhosis this pathway may also be impaired substantially. There is evidence that in cirrhosis other conjugation pathways may also be imp...Continue Reading

Citations

Jul 3, 1998·Journal of Clinical Pharmacology·A C KeungS J Weir
Sep 14, 2001·European Journal of Drug Metabolism and Pharmacokinetics·A M MazaJ L Pedraz
Aug 11, 2006·European Journal of Drug Metabolism and Pharmacokinetics·A KotsiouC Tesseromatis
May 12, 2005·European Journal of Clinical Pharmacology·Nenad SarapaKourosh Parivar
Sep 3, 2008·European Journal of Clinical Pharmacology·Roger K Verbeeck
Jun 19, 2013·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Kasra Shakeri-NejadJasper Dingemanse
Nov 27, 1999·Molecular Aspects of Medicine·J A Hasler
Apr 6, 1999·Journal of Hepatology·E F ChooD J Morgan
Oct 12, 2001·Autonomic Neuroscience : Basic & Clinical·J K PhillipsC E Hill
Aug 13, 1998·Alimentary Pharmacology & Therapeutics·L H OttesenF Bendtsen
Dec 1, 1998·Journal of Clinical Pharmacy and Therapeutics·E Tanaka
Jul 25, 2000·Journal of Clinical Pharmacy and Therapeutics·N PoolsupT L Knight
Oct 24, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Daniel Y HungMichael S Roberts
Jun 3, 2008·The Journal of Antimicrobial Chemotherapy·Jürgen BarthOlaf Burkhardt
Jun 30, 2010·International Journal of Clinical Practice·H M NguyenD Q Pham
Apr 14, 1999·The Journal of Small Animal Practice·S A Center
Mar 10, 2000·Journal of Clinical Pharmacology·J S LillK Thakker
Apr 13, 2000·Journal of Clinical Pharmacology·P H SluggJ Necciari
Jan 11, 2003·Journal of Clinical Pharmacology·Paul L M van GiersbergenJasper Dingemanse
Apr 6, 2006·The AAPS Journal·Johan ArebergKarl-Heinz Molz
Apr 17, 2004·Clinical Pharmacokinetics·Catherine C Crone, Geoffrey M Gabriel
Feb 22, 2012·Clinical Pharmacokinetics·Yan-Ling He
Oct 1, 2013·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Bruce CharlesRoss Norris
Sep 2, 1998·European Journal of Drug Metabolism and Pharmacokinetics·C PuozzoM Amouretti
Mar 7, 2002·British Journal of Clinical Pharmacology·Gary J MuirheadBernhard Rouviex
Jan 28, 2012·Expert Opinion on Drug Metabolism & Toxicology·John D Clarke, Nathan J Cherrington
Jul 8, 2010·Expert Opinion on Drug Metabolism & Toxicology·Pietro PalatiniSara De Martin
Feb 19, 2016·European Journal of Clinical Pharmacology·Naglaa M El-LakkanySanaa S Botros
Mar 5, 2004·British Journal of Clinical Pharmacology·Jasper Dingemanse, Paul L M van Giersbergen
Apr 18, 2003·Critical Care Clinics·Anatoli KraskoSteven Bonvino
Dec 22, 1999·Regulatory Toxicology and Pharmacology : RTP·E Dybing, E J Søderlund
Apr 16, 2016·Expert Opinion on Drug Metabolism & Toxicology·L G FrankenB C P Koch
Jun 18, 2016·European Journal of Drug Metabolism and Pharmacokinetics·Muhammad Fawad RasoolStephanie Läer
Aug 6, 2016·Journal of Palliative Medicine·Anniek D MasmanTeun van Gelder

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenocortical Carcinoma

Hepatocellular carcinoma is the most common type of primary liver cancer and frequently occurs in individuals with chronic liver diseases like cirrhosis. Here is the latest research.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.